Cytokinetics Announces Opening of Next Phase II Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

Cytokinetics has opened enrollment for an ALS Phase II clinical trial of CK-2017357, a fast skeletal muscle troponin activator. By increasing the force of a skeletal muscle’s reaction to input from a motor neuron, the drug aims to delay loss of muscle control and reduce muscle fatigue. The Phase II trial expects to enroll 24 patients at facilities across the United States and will test the safety and efficacy of the treatment.

Click here to read more.

Share this: